Clinical Trial: Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Innate Immunity and RSV Infection in Children

Brief Summary: In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.

Detailed Summary: Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the first 3 years of life. There are significant social and health care costs associated with RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die annually. Several longitudinal studies have also suggested that children who have RSV-LRIs are at substantially increased risk of developing asthma in the first 3 years after infection and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate the innate immune response through the pattern recognition receptor, Toll like receptor-4 (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It has been suggested that such a mechanism may result in altered immune responses to RSV infection and different clinical outcomes. This research has direct application to improving our understanding of bronchiolitis in early childhood, particularly those factors that influence severity of the disease, and may have implications for possible therapy of patients with bronchiolitis in the future.
Sponsor: University of Wisconsin, Madison

Current Primary Outcome:

  • Nasal Interferon (IFN)-a2 [ Time Frame: 1-5 days during acute illness (not after day 5 of illness) ]
    Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.
  • Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression [ Time Frame: 1-5 days during acute illness (not after day 5 of illness) ]
    IL-2 measured from nasal lavage samples by Luminex multiplex assay


Original Primary Outcome: Cytokine and chemokine levels in nasal secretions [ Time Frame: 1-5 days during acute illness ]

Current Secondary Outcome:

Original Secondary Outcome: Cytokine and chemokine levels in supernatant from stimulated peripheral mononuclear cell cultures [ Time Frame: 3-9 weeks after acute illness ]

Information By: University of Wisconsin, Madison

Dates:
Date Received: January 3, 2008
Date Started: November 2003
Date Completion:
Last Updated: September 30, 2015
Last Verified: September 2015